Chargement en cours...
Tofacitinib in Treatment-Refractory Moderate to Severe Ulcerative Colitis: Real-World Experience from a Retrospective Multicenter Observational Study
(1) Background: Tofacitinib is approved in Europe for the treatment of adults with moderately to severely active ulcerative colitis since 2018. Real-world efficacy and safety data are currently scarce. (2) Methods: We performed a retrospective multicenter study at three German tertiary outpatient cl...
Enregistré dans:
| Publié dans: | J Clin Med |
|---|---|
| Auteurs principaux: | , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
MDPI
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7408885/ https://ncbi.nlm.nih.gov/pubmed/32664204 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9072177 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|